Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRKR Marker Therapeutics, Inc.

Trading 06-11 09:34:36 EDT

1.42

-0.01

-0.70%

High1.42	Low1.42	Vol4.24K
Open1.42	D1 Closing1.43	Amplitude0.00%
Mkt Cap23.68M	Tradable Cap20.05M	Total Shares16.67M
T/O6.02K	T/O Rate0.03%	Tradable Shares14.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MRKR","market":"US","secType":"STK","nameCN":"Marker Therapeutics, Inc.","latestPrice":1.42,"timestamp":1781184830227,"preClose":1.43,"halted":0,"volume":4237,"delay":0,"changeRate":-0.006993006993007,"floatShares":14120600,"shares":16673100,"eps":-0.6535495,"marketStatus":"Trading","change":-0.01,"latestTime":"06-11 09:34:36 EDT","open":1.42,"high":1.42,"low":1.42,"amount":6016.5548295,"amplitude":0,"askPrice":1.43,"askSize":205,"bidPrice":1.42,"bidSize":6288,"shortable":3,"etf":0,"ttmEps":-0.6535495,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781208000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.42,"preClose":1.43,"latestTime":"08:18 EDT","volume":50,"amount":71,"timestamp":1781180282576,"change":-0.01,"changeRate":-0.006993,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.445,"preClose":1.43,"latestTime":"17:34 EDT","volume":504,"amount":728.2457,"timestamp":1781127263974,"change":0.015,"changeRate":0.01049,"amplitude":0.01049},"volumeRatio":6.287714,"impliedVol":3.5652,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/MRKR","defaultTab":"news","newsList":[{"id":"2635055850","title":"Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055850","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635055850?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:16","pubTimestamp":1778883419,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMarker Therapeutics Inc MRKR.OQ reported a quarterly adjusted loss of 16 cents per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S29G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058443","title":"Marker Therapeutics Q1 FY26 net loss narrows 28% to USD 3.18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058443","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058443?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:05","pubTimestamp":1778879146,"startTime":"0","endTime":"0","summary":"Marker Therapeutics posted a Q1 net loss of USD 3.18 million, narrowing 28% year over year.Operating loss narrowed 18% to USD 4.07 million as operating expenses fell 18% to USD 4.07 million.Research and development expense dipped 9% to USD 2.84 million; general and administrative costs dropped 10% to USD 1.23 million.Grant income more than doubled to USD 751,691, while cash, cash equivalents, and restricted cash declined to USD 15.64 million at March 31, 2026.Marker said it expects to fund operations into Q1 2027, while preparing for a larger pivotal lymphoma trial in 2026 and scaling MT-601 manufacturing via a Cellipont Bioservices agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the origina","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLHgDD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258869","title":"Marker Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258869","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258869?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:47","pubTimestamp":1778532427,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to  show a rise in quarterly revenue when it reports  results o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969645","title":"Marker Therapeutics shareholders approved charter amendment boosting authorized common stock to 130 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969645","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969645?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:42","pubTimestamp":1777927320,"startTime":"0","endTime":"0","summary":"Marker Therapeutics held its annual shareholder meeting on May 1, 2026.Shareholders adopted an amendment to increase authorized Common Stock to 130,000,000 shares from 30,000,000 shares; company reported this approval, without stating that any new shares have been issued.A separate charter amendment to revise voting threshold for future increases or decreases of Common Stock failed to win approval.Shareholders also authorized adjournment of meeting if support for authorized-share increase had been insufficient.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8f7rF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620329858","title":"BRIEF-Marker Therapeutics FY Basic EPS USD -0.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2620329858","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620329858?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:32","pubTimestamp":1773869535,"startTime":"0","endTime":"0","summary":"BRIEF-Marker Therapeutics FY Basic EPS USD -0.79\n\n\nMar 18 (Reuters) - Marker Therapeutics FY net income USD -12.2 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nPLX46483A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620328298","title":"Marker Therapeutics FY Net Income USD -12.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620328298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620328298?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:31","pubTimestamp":1773869490,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nPLX46483A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429837","title":"Press Release: Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429837","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429837?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:31","pubTimestamp":1773869460,"startTime":"0","endTime":"0","summary":"Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses. Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer. Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo. HOUSTON, March 18, 2026  -- Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today announced corporate updates and financial results for the year ended December 31, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4109","IE00B95QR487.USD","MRKR","IE00B45NX917.SGD","IE00BD0PCF45.HKD","LU0690374615.EUR","BK4142","GB00B4LPDJ14.GBP","LU2463526074.USD","IE00B0T0GQ85.USD","BK4585","LU0690374961.EUR","BK4539","GB00B4QBRK32.GBP","BK4202","ASH","LU2404859741.USD","LENZ","BK4139","LU2404859667.USD","LU1718418525.SGD","IE00B1G9WX41.USD","BK4588","BK4007","MAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620845298","title":"Marker Therapeutics FY 2025 net loss widens 13% to USD 12.16 million as grant income falls 46% to USD 3.55 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620845298","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620845298?lang=en_us&edition=fundamental","pubTime":"2026-03-19 05:28","pubTimestamp":1773869320,"startTime":"0","endTime":"0","summary":"Marker Therapeutics filed an annual report on Form 10-K reporting FY 2025 results, including grant income of USD 3.55 million, down 46%. Net loss for FY 2025 was USD 12.16 million, and net loss per share was USD 0.79. Research and development expense for FY 2025 was USD 11.8 million, down 12% primarily due to a net USD 3.2 million decrease in clinical trial expenses, mainly related to the AML study. Cash, cash equivalents, and restricted cash totaled USD 17.04 million at Dec. 31, 2025, and the company said it expects to fund operating expenses and capital expenditure requirements through Q4 2026, assuming no additional grant funds are received. Marker said the Phase 1 APOLLO study of MT-601 in relapsed lymphoma showed objective responses and a favorable safety profile with and without lymphodepletion, and it also reported first patient treatment in its off-the-shelf MT-401-OTS program with preliminary safety data.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLWl6D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618614299","title":"Marker Therapeutics Inc. Announces Annual Stockholder Meeting Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2618614299","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618614299?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:00","pubTimestamp":1773176425,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLbtR9yC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618600931","title":"H.C. Wainwright Sticks to Its Buy Rating for Marker Therapeutics (MRKR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600931?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:37","pubTimestamp":1773139033,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Marker Therapeutics, with a price target of $10.00. Ac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-marker-therapeutics-mrkr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-marker-therapeutics-mrkr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610599950","title":"High Growth Tech Stocks In The US February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610599950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610599950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 01:08","pubTimestamp":1770829713,"startTime":"0","endTime":"0","summary":"As February 2026 begins, the U.S. stock market has seen a robust start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, reflecting positive investor sentiment despite recent economic uncertainties such as government shutdowns and changes in Federal Reserve leadership. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential, adaptability to market shifts, and financial...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/high-growth-tech-stocks-in-the-us-february-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/high-growth-tech-stocks-in-the-us-february-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4613","PLT","IE00B894F039.SGD","BK4547","LU1861558580.USD","PLTD","VRDN","PLTZ","PLTW","PLOO","PLYY","WDAY","BK4009","BK4588","MNTN","PTIR","PLTY","STOK","PLTG","RDDT","BK4023","BK4543","IE00B19Z9Z06.USD","PLTA","IE00BZ9MQY76.HKD","PLTR","BK4585","LU1861559042.SGD","IE00B19Z9P08.USD","BK4139","PLTU","MRKR","CRC","SNDK","PCOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606212007","title":"Marker Therapeutics Receives NIH and CPRIT Funding for Pancreatic Cancer Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2606212007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606212007?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:01","pubTimestamp":1769428902,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has received funding from the National Institutes of Health  Small Business Innovation Research  program and the Cancer Prevention and Research Institute of Texas  to support its upcoming pancreatic cancer program. The company plans to initiate a clinical study in the first half of 2026, building on results from a Baylor College of Medicine-led study that utilized Marker’s Multi-Antigen Targeted T cell technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9q0Whj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4585","SG9999014039.USD","LU2210149790.SGD","BK4588","NDAQ","MRKR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","BK4139","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601886852","title":"Marker Therapeutics Secures NIH and CPRIT Funding for Pancreatic Cancer Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886852?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:01","pubTimestamp":1767614501,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has secured non-dilutive funding from the National Institutes of Health  Small Business Innovation Research  program and the Cancer Prevention and Research Institute of Texas  to support its pancreatic cancer program. This funding will enable the company to proceed with clinical development of its Multi-Antigen Targeted T cell  therapy for pancreatic cancer without impacting its financial runway or ongoing efforts in lymphoma trials. No other beneficiary organizations are mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9SWbSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","MRKR","BK4139","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4585","NDAQ","BK4112","LU0314104364.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.markertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0593},{"period":"6month","weight":-0.0272},{"period":"1year","weight":-0.1538},{"period":"ytd","weight":-0.0403}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.055182},{"month":2,"riseRate":0.3,"avgChangeRate":-0.076284},{"month":3,"riseRate":0.4,"avgChangeRate":-0.084453},{"month":4,"riseRate":0.4,"avgChangeRate":0.010046},{"month":5,"riseRate":0.6,"avgChangeRate":0.224685},{"month":6,"riseRate":0.5,"avgChangeRate":0.22338},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.078392},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035761},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.06731},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.021955},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.047609},{"month":12,"riseRate":0.3,"avgChangeRate":0.054056}],"exchange":"NASDAQ","name":"Marker Therapeutics, Inc.","nameEN":"Marker Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Marker Therapeutics, Inc.,MRKR,Marker Therapeutics, Inc.股票,Marker Therapeutics, Inc.股票老虎,Marker Therapeutics, Inc.股票老虎国际,Marker Therapeutics, Inc.行情,Marker Therapeutics, Inc.股票行情,Marker Therapeutics, Inc.股价,Marker Therapeutics, Inc.股市,Marker Therapeutics, Inc.股票价格,Marker Therapeutics, Inc.股票交易,Marker Therapeutics, Inc.股票购买,Marker Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction